New research identifies specific genetic changes that can increase a person’s risk of breast and ovarian cancers, to help guide clinical decision-making.
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...